HC Wainwright & Co. Reiterates Buy on Edesa Biotech, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Edesa Biotech and maintained a price target of $21.
August 20, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Edesa Biotech, maintaining a price target of $21, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $21 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Edesa Biotech's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100